Valneva Shares Face Legal Scrutiny Amid Declining Valuation

Valneva stock down 29% YTD as US law firms investigate potential securities fraud following failed Phase 3 Lyme vaccine trial. CEO pushes for FDA approval despite missed endpoint.

The period following the World Vaccine Congress in Washington has brought fresh challenges for Valneva. The biotech company now faces legal investigations initiated by specialized US law firms examining potential securities fraud. This development adds another layer of pressure for the firm's equity, which has already depreciated by approximately 29% since the start of the year.

Legal Fallout from Clinical Trial Results

A significant decline in share value occurred on March 23, 2026, triggered by Valneva's announcement of Phase 3 data for its Lyme disease vaccine candidate, VLA15. The stock temporarily plummeted more than 37% after the trial failed to meet its primary endpoint. This event has prompted firms including Pomerantz LLP and Bronstein, Gewirtz & Grossman to investigate whether the company and its executives may have misled investors regarding the true data picture from the "VALOR" study. Such inquiries frequently evolve into class-action lawsuits, which can burden management with substantial costs and distractions.

During the recent congress, CEO Thomas Lingelbach addressed the setback. He reiterated the company's continued pursuit of regulatory approval for the vaccine, developed in partnership with Pfizer, despite the disappointing results. Lingelbach argued that an efficacy rate of 73.2% provides a solid foundation for discussions with the U.S. Food and Drug Administration (FDA). He suggested the regulator should show flexibility in its data assessment, given the significant unmet medical need for Lyme disease prevention. Valneva maintains its plan to submit marketing applications in the second half of 2026.

Regulatory Hurdles and a Second Product Pillar

Alongside its Lyme vaccine efforts, Valneva highlighted progress for its single-dose Chikungunya vaccine, IXCHIQ, at the industry event. The company presented real-world data from a pilot campaign in Brazil, where over 12,000 individuals were vaccinated, to support the long-term safety profile of the product. However, the company is concurrently navigating regulatory queries in other markets, most recently in the United Kingdom.

The dual pressures of legal uncertainty and ongoing questions about the FDA's stance on its lead product are reflected in the stock's performance. Trading well below its long-term averages, the shares currently sit more than 47% below their 52-week high of €5.16. Whether discussions with the FDA later this year can catalyze a meaningful recovery will largely depend on the regulatory latitude granted by the agency. A further determining factor will be the extent to which the ongoing legal investigations impact the company in the interim.